Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-25 (Hyzetimibe) in Primary Hypercholesterolemia
NCT02087917Phase 2Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Mar 2014
- Primary completion
- Sep 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hybutimibe in hypercholesterolemia (5 arms), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoint: Percent change from baseline in LDL-C at 4 weeks. Started Mar 2014; status: completed.
02
Drugs
hybutimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02087917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02087917.